✦ LIBER ✦

Ibandronate® in the adjuvant treatment of locally advanced prostate carcinoma (PCa)

✍ Scribed by T. Lindenmeir; F. Reiher; O. Rau; Th. Nelius; E.P. Allhoff

Book ID: 116319490
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 51 KB
Volume: 38
Category: Article
ISSN: 8756-3282
DOI: 10.1016/j.bone.2006.01.040

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant therapy with ibandronate in pat

Adjuvant therapy with ibandronate in patients with locally advanced prostate cancer

✍ T. Lindenmeir; M. Ulrich; O. Rau; F. Reiher; E.P. Allhoff 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Dose escalation in locally advanced carc

Dose escalation in locally advanced carcinoma of the prostate

✍ Angel I. Blanco; Jeff M. Michalski 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Integrated treatment in locally advanced

Integrated treatment in locally advanced carcinoma of the oropharynx

✍ Laura Lanza; Lucio Rizzi; Domenico Durso; Antonio Occhini; Marco Benazzo; Carmin 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

Acute Toxicity of Adjuvant Radiotherapy

Acute Toxicity of Adjuvant Radiotherapy in Locally Advanced Differentiated Thyroid Carcinoma

✍ Andreas Schuck; Martin Biermann; MichaelaK. Pixberg; StefanB. Müller; Achim Hein 📂 Article 📅 2003 🏛 Springer 🌐 German ⚖ 379 KB

Interstitial iodine-125 radiation withou

Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

✍ Bhadrasain Vikram 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

Interstitial iodine-125 radiation withou

Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

✍ Haakon Ragde; John C. Blasko; Peter D. Grimm; Gerald M. Kenny; John E. Sylvester 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

## Background: This study was designed to evaluate the efficacy of iodine-125 interstitial radiation in the treatment of prostate carcinoma classified as t1 or t2. ## Methods: One hundred twenty-six consecutive patients with adenocarcinoma of the prostate (t1, 23%; t2, 77%) were treated with iodi